Paratek Pharmaceuticals

September 27, 2018

Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions

October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a make-or-break FDA verdict.

August 06, 2018

Almirall spots an opportunity

The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.

August 03, 2018

Upcoming events – Antibiotics from Insmed and Paratek face consecutive panels

Make-or-break FDA adcoms beckon for two antibiotics.

February 14, 2018

Intravenous inferiority makes it two failures for Tetraphase

November 30, 2017

Medicines Company shows that there’s money in antibiotics after all

October 18, 2017

Interview – Nabriva comes out fighting

September 19, 2017

A call for help from the antibiotics makers

July 21, 2017

Snippet roundup: a lingering Lingo and two more US green lights

April 07, 2017

Snippet roundup: Merck gets Tecos knockback, Gottlieb moves towards FDA hotseat

June 17, 2016

Paratek hopes antibiotic success is infectious

September 21, 2015

ICAAC – Merck & Co scores with non-antibiotic antibacterial

Load More